Post

Transition Plan for Medical Devices Distributed Under COVID-19 Emergency Enforcement Policies

This guidance outlines FDA's transition plan for medical devices that were distributed under enforcement policies issued during the COVID-19 public health emergency (PHE). It applies to devices falling within enforcement policies described in 17 specific guidances (List 1) and aims to provide an orderly transition from emergency policies to normal operations after the PHE expires.

  1. Begin compliance with adverse event reporting requirements immediately if not already doing so
  2. Before Phase 2 (90 days after implementation):
    • Register establishments and list devices
    • Implement correction and removal reporting
    • Submit Notification of Intent for applicable life-supporting devices
    • Begin preparing marketing submissions
  3. Before Phase 3 (180 days after implementation):
    • Submit and have marketing submission accepted by FDA
    • Include Transition Implementation Plan with submission
    • Ensure compliance with all applicable regulatory requirements
  4. After Phase 3:
    • Ensure full compliance with all applicable regulations
    • Update labeling as required
    • Implement Transition Implementation Plan based on FDA decision
    • Cease distribution if marketing submission not accepted or receives negative decision
  5. Throughout transition:
    • Maintain communication with stakeholders
    • Monitor and comply with applicable quality system requirements
    • Keep records of distributed devices
    • Follow applicable adverse event reporting requirements

Key Considerations

Labelling

  • Devices must be labeled as described in the relevant List 1 guidance while under FDA review
  • Updated labeling required after marketing authorization that accurately describes product features and regulatory status
  • For reusable life-supporting/life-sustaining devices, stakeholders should be provided opportunity to request physical copy of updated labeling without additional cost

Safety

  • Manufacturers must comply with adverse event reporting requirements under 21 CFR Part 803
  • Must follow correction and removal requirements under 21 CFR Part 806
  • Quality System requirements under 21 CFR Part 820 must be met

Other considerations

  • 21 CFR Part 803: Medical Device Reporting
  • 21 CFR Part 806: Reports of Corrections and Removals
  • 21 CFR Part 807: Establishment Registration and Device Listing
  • 21 CFR Part 820: Quality System Regulation
  • 21 CFR Part 801: Labeling

Original guidance

  • Transition Plan for Medical Devices Distributed Under COVID-19 Emergency Enforcement Policies
  • HTML / PDF
  • Issue date: 2023-03-27
  • Last changed date: 2023-03-24
  • Status: FINAL
  • Official FDA topics: Medical Devices, Premarket, Coronavirus, Postmarket
  • ReguVirta summary file ID: 588903e0169885a77e0e0399b4e3dbc0
This post is licensed under CC BY 4.0 by the author.